Noah Stern

Dr. Noah Stern


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

21 December 2021 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
NSNoah Stern
Noah Stern
TLTina Luu Ly
Tina Luu Ly
BWBlayne Welk
Blayne Welk
JCJoseph Chin
Joseph Chin
DBDale Ballucci
Dale Ballucci
NPNicholas Power
Nicholas Power
Despite extensive research, age, family history, race and ethnicity, and certain genetic sequence variants remain the only currently well-established risk factors for prostate cancer. Black men are purported to have an increased risk of early and aggressive prostate cancer. This higher risk classification for Black men has resulted in recommendations for earlier prostate cancer screening and evidence of distinctive treatment patterns.1,2 However, the underlying data for these recommendations lack high-quality evidence, rendering the validity of these conclusions uncertain. Data from the Canadian health care system are well suited for studying the association of race and ethnicity and prostate cancer mortality, owing to Canada’s diverse population and universal health care model.

3 August 2025 in Sexual Medicine Reviews
Verified
Journal Article
Open access
NSNoah Stern
Noah Stern
PBPetar Bajic
Petar Bajic
JCJeffrey Campbell
Jeffrey Campbell
PCPaolo Capogrosso
Paolo Capogrosso
TDTrustin Domes
Trustin Domes
GBGerald Brock
Gerald Brock
Introduction: Treatment of erectile dysfunction is based on pharmacotherapy for most patients. Aim: To review the current data on pharmacotherapy for erectile dysfunction based on efficacy, psychosocial outcomes, and safety outcomes. Methods: A review of the literature was undertaken by the committee members. All related articles were critically analyzed and discussed, and consensus statements were developed after presentation at the 2024 ICSM. Results: Eight recommendations are provided with the corresponding level of evidence and grade of recommendation. Conclusions: The management of erectile dysfunction should be personalized to address the psychosocial needs and expectations of both the patient and their partner. PDE5 inhibitors remain the first-line treatment for most men, while intracavernosal injections, vacuum erection devices, and penile prostheses serve as second-line options, with treatment decisions guided by patient preferences. Key recommendations are summarized in table 1.


22 February 2023 in Endocrines
Verified
Journal Article
Open access
PDF file
MPMichael Pignanelli
Michael Pignanelli
NSNoah Stern
Noah Stern
Gerald BrockGerald Brock
Gerald Brock
Erectile physiology, in order to function normally, requires the complex coordination of endocrine, neurocognitive, neuromuscular and vascular mechanisms. Testosterone (T) influences male sexuality as well as penile erections at multiple levels, including a direct influence on the nitric oxide synthase (NOS)/cGMP/phosphodiesterase 5 pathway in the penis. However, the precise role of testosterone replacement (TRT) to “salvage” men with mixed ED failing phosphdiesterase-5 inhibitors (PDE5i) remains unclear. We conducted a scoping review identifying the rationale for TRT in ED failing PDE5i, and we critically discuss clinical trials that have examined TRT in the setting of PDE5i use. Overall, TRT replacement appears to be well tolerated and may enhance the response to PDE5i and quality of life, particularly for men with mixed ED, and particularly among men with very low levels of testosterone. However, most of the available literature examines concurrent TRT alone or simultaneous TRT + PDE5i usage, without necessarily selecting for PDE5i failure cases. The present studies are limited to heterogenous studies with small sample sizes, without an exact predominant etiologic factor causing ED. Furthermore, studies showing the most benefit are non-placebo-controlled trials; however, the correction of more profound hypogonadism may lead to an improved response to PDE5i. Stronger conclusions would require properly selected patient populations and larger placebo-controlled RCTs.

29 August 2019 in Medical Sciences
Verified
Journal Article
Open access
PDF file
SSSamir Sami
Samir Sami
NSNoah Stern
Noah Stern
APAndrew Di Pierdomenico
Andrew Di Pierdomenico
BKBrandon Katz
Brandon Katz
Gerald BrockGerald Brock
Gerald Brock
Introduction: Optimizing erectile dysfunction (ED) remains a clinically significant endeavor as insufficient outcomes from oral, injectable and even surgical approaches to treatment remain less than ideal. In this report, we integrate evolving knowledge and provide an algorithmic approach for the clinician to fine-tune management. Methods: We performed a PubMed and Medline search of Erectile Dysfunction treatment optimization, enhanced patient efficacy for ED, and why men fail ED treatment. All relevant papers for the past two decades were reviewed. Results: Establishing the goals and objectives of the patient and partner while providing detailed instructions for treatment can minimize failures and create an environment that allows treatment optimization. A thorough work-up may identify reversible or contributing causes. We identified several areas where treatment of ED could be optimized. These include; management of associated medical conditions, lifestyle improvements, PDE5 inhibitor prescription strategies, management of hypogonadism and the initiation of intracavernosal injection therapy (ICI). Conclusions: In our view, once a man presents for help to the clinician, use of the simple strategies identified in this review to optimize the tolerability, safety and effectiveness of the selected treatment should result in enhanced patient and partner satisfaction, with improved outcomes.